Total revenues reached NOK 29.8 million, an increase of 24% year-over-year, driven by robust performance across both Biomanufacturing and Molecular Tools segments. A significant milestone following the end of the quarter was the signing of an exclusive European partnership agreement with Brenntag, expanding ArcticZymes’ reach in the biomanufacturing market for advanced therapies.
Key Financials (Q3 and 9M 2025)
- Total revenue: NOK 29.8 million, up 24% from NOK 24.1 million in Q3 2024. First nine months (9M) 2025 total revenue reached NOK 83.6 million, up 2% from NOK 81.7 million in 9M 2024.
- Sales revenue: NOK 28.5 million, up 22% from NOK 23.3 million in Q3 2024.
- Year-to-date sales totalled NOK 78.5 million, down 1.6% compared to NOK 79.8 million in the same period of 2024.
- EBITDA: Improved to NOK 3.5 million (Q3 2024: NOK -2.3 million), reflecting strong operational execution and cost discipline. Year-to-date EBITDA rose 42 % to NOK 3.7 million (9M 2024: NOK 2.6 million).
- Cash flow: Cash position strengthened, with net cash flow from operations of NOK 7.8 million in Q3 and NOK 17.2 million year-to-date (9M 2024: NOK 3.2 million), bringing total cash holdings to NOK 182.3 million and an additional NOK 76.0 million held in low-risk, liquid interest-bearing funds.
Business Segment highlights
- Molecular Tools: Revenues of NOK 15.4 million, up 45% from NOK 10.6 million in Q3 2024. Growth was primarily driven by renewed orders from a key account, but other accounts contributed to the growth as well.
- Biomanufacturing: Sales of NOK 13.1 million, up 2% versus Q3 2024 (Q3 2024: NOK 12.8 million), with 23% year-to-date growth versus 2024.
- GMP-grade products grew 173% quarter-on-quarter, now representing 26% of Biomanufacturing sales, validating our GMP product strategy and supporting customers as they advance into later stages of drug development.
Events After the End of the Quarter
- ArcticZymes has signed an exclusive distribution agreement with Brenntag for the Salt Active Nucleases (SAN) in Europe.
- Brenntag, a global market leader in chemical and ingredients distribution with a vast European network, brings strong capabilities and reach across the life sciences and biopharmaceutical sectors
- Brenntag is appointed as the sole distributor of ArcticZymes nucleases in Europe and will offer only ArcticZymes nucleases, ensuring full exclusivity on both sides
- The partnership will expand ArcticZymes’ market reach, accelerate customer access, and strengthen its position in key bioprocessing and biomanufacturing segments.
- By leveraging Brenntag’s commercial infrastructure, technical expertise, and established customer relationships, ArcticZymes aims to enhance market penetration and drive long-term growth in Europe
- ArcticZymes will continue to sell SAN directly to customers in Europe, complementing Brenntag’s distribution activities to ensure broad market coverage, customer support and feedback
CEO Commentary
“Q3 reflects continued execution of our customer-centric strategy and another solid quarter of progress across both Biomanufacturing and Molecular Tools,” said Michael Akoh, CEO of ArcticZymes Technologies. “We delivered strong topline growth and improved profitability, underpinned by robust demand for our GMP-grade products and a notable growth recovery in the Molecular Tools segment.”
“Our new partnership with Brenntag marks an important milestone in strengthening our European presence within biomanufacturing,” Akoh continued. “It underscores the successful execution of our channel strategy - extending our market reach and deepening partnerships with customers as we position ArcticZymes for long-term, sustainable growth.”
Outlook
- Continued long term sales momentum supported by increasing adoption of GMP-grade products, CDMO platform integration and orders from a key Molecular Tools account.
- Enhanced European market access through the new Brenntag partnership, expanding reach within biomanufacturing.
- Ongoing enzyme application expansion into new areas such as metagenomics, driving long-term growth potential of the current enzyme portfolio
The access the report click here.
To access the Q3 presentation click here.
To access the Q3 webcast click here.
